Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

G. Andrisani1, E. Gremese2, L. Guidi1, A. Papa1, M. Marzo1, C. Felice1, D. Pugliese1, A. Armuzzi1

1Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Catholic University; 2Rheumatology Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy

SUMMARY
Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ulcerative colitis (UC). Among all the biological agents available, nine have been currently approved for the treatment of RA. Conversely, only Infliximab and recently Adalimumab have been approved for UC. In particular, the efficacy of Adalimumab in UC has been demonstrated by both recent randomized controlled trials and real-life studies. Moreover, Adalimumab is a well-established treatment for RA. Herein, we describe a patient with RA and UC treated successfully with ADA.

Key words: Ulcerative colitis, Rheumatoid arthritis, Adalimumab.

INTRODUCTION
Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ulcerative colitis (UC). Among all the biological agents available, nine have been currently approved for the treatment of RA. Conversely, only Infliximab and recently Adalimumab have been approved for UC. In particular, the efficacy of Adalimumab in UC has been demonstrated by both recent randomized controlled trials and real-life studies. Moreover, Adalimumab is a well-established treatment for RA. Herein, we describe a patient with RA and UC treated successfully with ADA.

CASE REPORT
Here we report the case of a 54-year-old woman who was admitted to our Unit for abdominal pain, fever, rectal bleeding and diffuse arthralgia. She was diagnosed with seronegative RA since the age of 37, on the basis of peripheral (hand and feet) symmetric polyarthritis, according to 1987 the American College of Rheumatology criteria (11). She was previously treated with long-term steroid therapy and methotrexate (discontinued for disease remission), and then with hydroxichloroquine (6 mg/kg/day) until the admission at our unit, with sufficient control of RA disease. Six months before admission (March 2007) she had been diagnosed with extensive ulcerative colitis according to clinical symptoms and endoscopic/histological findings. Ileocolonoscopy showed normal terminal
ileum and diffuse erosions and friability of the mucosa, which was spontaneously bleeding over the entire colonic tract. Multiple biopsies revealed distortion of gland architecture, mucin depletion, marked inflammatory infiltration in the lamina propria and cryptitis. Consistent with this diagnosis, abdominal ultrasonography depicted mild parietal thickening of the colon and normal thickness of the ileum. She was started on treatment with oral and topical mesalamine after diagnosis and then received one course of oral corticosteroids with partial improvement of symptoms, which relapsed during tapering.

In September 2007, the severity of UC-related symptoms (8 bowel movements/day with blood and mild fever) led to admission to our Unit. She presented also peripheral arthralgias. Physical examination revealed tachycardia and tenderness in the left abdominal quadrants with no rebound or guarding. Abdominal X ray did not show free air, air fluid levels, colonic or small bowel dilation.

Main laboratory findings revealed moderate anemia (hemoglobin: 10.7 g/dL), increase of C-reactive protein level of (34.8 mg/L) and erythrocyte sedimentation rate (ESR) (42 mm/h), low serum albumin levels (3.2 g/dL), Stool culture and C. difficile toxin tests were negative. On the basis of clinical and biochemical features, the patient was administered intravenous prednisolone (1 mg/kg/day) for seven days, but no significant benefit was observed. Therefore, anti-TNF treatment with infliximab (5 mg/kg) and azathioprine (2 mg/kg) was started and steroid then tapered. After three months, azathioprine was stopped due to an increase in liver enzyme levels. At that time the patient was experiencing relief of gastrointestinal symptoms, but persistence of arthralgia, after an initial improvement.

In April 2008, a relapse of bowel symptoms required another oral steroid cycle. A few months later (June 2008) the patient developed an infusion reaction to infliximab (skin rash and dyspnea) and, therefore, the drug was discontinued. She underwent ileocolonoscopy that showed purulent mucous secretions, dyschromic and hyperemic mucosa in the right and transverse colon, swollen ileo-caecal valve and several erosions and ulcers in sigmoid colon and rectum (Fig. 1). Furthermore, she was evaluated by a rheumatologist for the persistence of joint symptoms. The patient presented 12 swollen and 15 tender joints with a disease activity index on 28 joints (DAS28) of 6.8, indicating a high disease activity. Hand and feet x-rays showed characteristics RA joint erosions. No sacroiliitis was found and the lumbar spine was normal. The rheumatologist recommended methotrexate (15 mg/week), folic acid and methylprednisolone (16 mg/day), with only partial improvement.

Based on the intestinal symptoms and endoscopic findings observed on July 2008, the patient started adalimumab (ADA) subcutaneously, at the dosage of 160/80 mg as induction and then 40 mg every two weeks as maintenance, with considerable clinical improvement already after induction treatment (hemoglobin 12.6 g/dL, C-reactive protein 2.2 mg/L, ESR 10 mm/h). One year later, she underwent colonoscopy that showed diffuse hyperemia and decrease of vascular pattern. Multiple biopsies revealed mild chronic inflammatory infiltrate in the lamina propria and mild glandular atrophy, suggesting a condition of quiescent UC. The rheumatology evaluation was consistent with disease in remission (no swollen joints, 2 tender joints, DAS28 2.54). In view of the endoscopic picture and good clinical condition of the patient
Achievement of sustained deep remission with adalimumab

It was decided to continue treatment with ADA along with low doses of methotrexate (10 mg/week) and no steroid therapy. In December 2009, in accordance with rheumatologist, the patient discontinued methotrexate due to persistent RA remission. In August 2011, after 3 years of therapy with ADA, another colonoscopy was performed and the mucosa appeared healed throughout the entire colon (Fig. 2).

**DISCUSSION**

Among all the biological agents available, nine have been currently approved for the treatment of RA. Conversely, only two anti-tumor necrosis factor alpha (anti-TNF-α) agents, namely Infliximab and recently ADA, have been approved for the treatment of UC. In particular, the efficacy of ADA in UC has been demonstrated by both recent randomized controlled trials and real-life studies (12-16). Moreover, ADA is a well-established treatment for RA.

The described patient suffered from ulcerative pancolitis occurring during the course of a long-term history of RA, and was successfully treated with ADA after failure of other available drugs. Even if we consider only the gastrointestinal disease, the clinical features of this patient are quite difficult to manage from a medical point of view. In fact, the use of pharmacological therapies is limited and in cases of refractoriness the only other option for this patient is colectomy. Surgery is theoretically curative for UC but there are many possible post-operative complications and, even in the best outcome, the patient will have 4/5 bowel movements per day.

Moreover, in our case we have a complicating factor that is the association of RA. To date, no specific trials aiming to evaluate anti-TNF-α treatment in patients with RA and UC have been performed. To our knowledge, few cases of RA with concomitant UC have been reported, but none regarding a successful treatment with ADA (3-10). Some of these cases evaluate possible pathogenetic mechanism for the concomitance of the two diseases (3-5). One recent report highlights the further association of selective immunoglobulin A deficiency in a patient with long-standing RA, which developed UC (7). Sugisaki et al. describes a patient that was quite similar to the present case, but was successfully treated with mesalamine enema (6).

A further three reports describe treatment using a biological agent, but not specifically with anti-TNF-α to treat the two associated pathologies. Interestingly, two other studies reported the occurrence of UC a few months after treatment with abatacept (during a clinical trial) in patients with RA (8) and the onset of UC during the biologic treatment for RA currently used also to treat UC (9), respectively. Finally, a report by Mayer et al., describes a complex case of many overlapping syndromes: rheumatoid arthritis, ulcerative colitis, spondyloarthritis and systemic lupus erythematosus. However, in that case, ADA was introduced only after an urgent colectomy, performed for multidrug-resistant ulcerative colitis complicated with perforation, to treat arthritis (10).

In the current case, rheumatoid arthritis started many years before ulcerative colitis, and, until the onset of the intestinal disease, had a relatively benign course (with disease remission and discontinuation of therapy), although with the development of typical x-rays erosions, despite the seronegativity. After ulcerative colitis onset, rheumatoid arthritis seems to have had an accelerated course and a severe flare that does not re-
spond even to the first anti-TNFα therapy used, suggesting that the underlying mechanisms of inflammation in the two diseases are common. The use of adalimumab, also in presence of rheumatoid arthritis negative prognostic factors (i.e. high disease activity -DAS28 6.4-, x-rays erosions, long disease duration, non-response to the first anti-TNF), appears to be very effective.

In conclusion, considering the scarce data available so far, our case suggests that ADA can have a beneficial effect in patients with both ulcerative colitis and rheumatoid arthritis, refractory to conventional therapy. Furthermore, we also achieved mucosal healing that is, to date, one of the most ambitious goals in a patient with IBD. Future studies, including randomized clinical trials are needed to confirm our findings.

Conflict of interests: AA received consultancy from AbbVie and MSD; lecture fees from AbbVie, MSD, Chiesi, Ferring, Nycomed, and Otsuka; and educational grants from AbbVie and MSD. LG received educational grants from AbbVie, MSD. The authors report no other conflicts of interest.

Contributions: all authors contributed equally.

REFERENCES